Hypolipidemic therapy under special conditions: Acquired immune deficiency syndrome;Terapia hipolipemiante em situações especiais - Síndrome de imunodeficiência adquirida

Arquivos Brasileiros de Cardiologia

Volumn 85, Issue SUPPL. 5, 2005, Pages 58-61

  Yu, Pai Ching ^a   Calderaro, Daniela ^a   Lima, Enéas M O ^a   Caramelli, Bruno ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

AIDS; Dyslipidemia; HAART

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; BEZAFIBRATE; CYTOCHROME P450 3A4; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; PROTEINASE INHIBITOR; SIMVASTATIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOVASCULAR DISEASE; CORONARY RISK; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG METABOLISM; DRUG MONITORING; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFE EXPECTANCY; LIPID METABOLISM; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 31144463429     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/s0066-782x2005002400014     Document Type: Review

References (43)

1. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 2: 416-420.
2. Sposito A, Caramelli B, Sartori AM, Ramires JAF. Lipoprotein profile alteration in HIV positive patients. International Symposium on Infection and Atherosclerosis. Les Pensières, Veyrier du Lac, 1998.
3. Carr A, Cooper A. Adverse side effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
4. Smith JH, Martin J, Decker CF. Hiperlipidemia associated with the use of protease inhibitors. CID 2000; 31 (july): 207-208.
5. Periad D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100: 700-705.
6. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
7. Lenhard JM, Croom DK, Weiel JE, et al. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000; 20: 2625-2629.
8. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS.1999; 13: 63-70.
9. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy (Letter). AIDS. 1998;12:1393-1394.
10. Bernoche C, Ikeoka D, Monachini M, Durazzo A, Sartori A, Caramelli B. Dislipidemia associada ao uso de inibidores de protease em pacientes com AIDS: resultados com o uso de fenofibrato. Rev Soc Cardiol do Estado de São Paulo. 2001; 11: 26.
11. Caramelli B, Bernoche C, Sartori A, Sposito A, Santos R, Monochini M, Strabelli T, Uip D. Hyperlipidemia related to the use of HIV protease inhibitors: natural history and results from treatment with fenofibrate. Braz J Infect Dis. 2001 Dec; 5(6): 332-338.
12. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001 Sep; 51(3): 151-177.
13. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV and Montaner JSG. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population based HIV " AIDS treatment database.AIDS 2001; 15: 231-239.
14. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, risk factors and treatment. Scand. J. Infect. Dis 2000; 32: 111-123.
15. Panse I, Vasseeur E, Raffin-Sanson ML, Staroz F, Rouvix E, Saiag P. Lipodytrophy associated with protease inhibitors. Br. J Dermatol. 2000; 142: 496-500.
16. Carr A. Lipodistrophy in HIV-1 infected patients. Lancet 1999; 354: 867-870.
17. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hypeglicemia, hyperlipidemia and lipodystrophy: a 5-year cohort study. Arch. Intern. Med.2000; 160: 2050-2056.
18. Mullingan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune. Defic. Syndr. 2000; 23: 35-43.
19. Dubé MP, Sattler EF. Metabolic complications of antiretrovirals therapies. AIDS Clinical Care 1998; 10(6): 41-44.
20. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor associated hiperglycaemia. Lancet 1997; 350: 713-714.
21. Sereger S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27: 77-81.
22. Carr A, Samaras K, Chisholm DJ,Cooper DA. Pathogenesis of HIV-1-protease inhibitor associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351(9119): 1881-1883.
23. Rickerts V, Brodt H, Staszewski S, StilleW. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000; 5(8): 329-333.
24. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. (letter). Lancet 1998; 351: 1328.
25. Eriksson U, Opravil M, Amann FW, Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS 1998; 12: 2079-2080.
26. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999; 131: 548.
27. Muise A, Arbess G. The risk of myocardial infarction in HIV-infected patients receiving HAART: a case report. Int J STD AIDS 2001; 15: 329-334.
28. Holmberg S, Moorman A, Williamson JM, et al. Protease inhibitor use and adverse cardiovascular outcome in patients with HIV-1. Lancet 2002; 360: 1747-1748.
29. Currier J, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals: association with antiretroviral therapy. [Abstract]. Antiviral Ther 2002; 7: L37.
30. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
31. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
32. The Data Colletion on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
33. D'Arminio A, Sabin CA, Phillips NA, et al. D:A:D: Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18(13): 1811-1817.
34. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intim-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-1608.
35. III Diretrizes Brasileiras sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq. Bras. Cardiol. 2001;Volume 77 Suplemento III
36. Wilson PWF, D'Agostinho RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
37. Henry K, Melroe J, HuebeschJ, et al. Atorvastatin and gemfibrozil for protease inhibitor related lipid abnormalities. Lancet 1998; 352: 1031-1032.
38. Miller J, Carr A, Brown D, et al. A randomized, double blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertrygliceridemia. Eighth Conference on Retroviruses and Opportunistic Infections 2001, Chicago. [Abstract 540].
39. Thomas JC, Lopes-Virella MF, Del Bene VE, et al. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy 2000; 20: 727-734.
40. Caramelli B, de Bernoche CY, Sartori AM, Sposito AC, Santos RD, Monachini MC, Strabelli T, Uip D. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis 2001 Dec;5(6):332-8.
41. Lima EMO, Yu PC, Bernoche CYSM, Hayasahi I, Torricelli FCM, Hajjar LA, CalderaroD, Caramelli B. Bezafibrato no tratamento da dislipidemia associada à síndrome da imunodeficiência adquirida. Rev Soc Cardiol do Estado de São Paulo 2004;14(2): 28.
42. Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003; 17 (suppl 1): S162-S169.
43. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001; 344: 984-996.